Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Research output: Contribution to journalArticle

1 Scopus citations


Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.

Original languageEnglish (US)
JournalHematology/ Oncology and Stem Cell Therapy
StatePublished - Jan 1 2019



  • Acute Myeloid Leukemia
  • Allogeneic Stem Cell Transplant
  • Bone Marrow Transplant
  • FLT-3
  • Hypomethylating agent
  • Induction Chemotherapy
  • Leukemia
  • Myelodysplastic syndrome
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this